Impact of Dexmedetomidine on Acute Kidney Injury Following Living Donor Liver Transplantation
Study Details
Study Description
Brief Summary
Acute kidney injury (AKI) following liver transplantation (LT) is associated with increased costs, morbidity, and mortality. Dexmedetomidine has known have anti-inflammatory effect and has been shown to ameliorate IRI in several organs. However, the impact of Dexmedetomidine on AKI after LT is not determined yet. Therefore, this study aims to observe the renal protective effects of Dexmedetomidine after LT.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 4 |
Detailed Description
Acute kidney injury (AKI) following liver transplantation (LT) has shown a wide range of between 17% and 95% and is associated with increased costs, morbidity, and mortality. The etiology of AKI after LT is multifactorial. Among these factors, renal ischemia-reperfusion injury (IRI) caused by perioperative renal hypoperfusion is considered as one of the most important independent risk factors and recent reports have indicated that IRI is associated with an inflammatory cascade. Dexmedetomidine which is a highly selective agonist of α2-adrenergic receptors has known have anti-inflammatory effect and has been shown to ameliorate IRI in several organs. However, the impact of Dexmedetomidine on AKI after LT is not determined yet. Therefore, this study aims to observe the renal protective effects of Dexmedetomidine after LT.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| No Intervention: control group The control group was given normal saline by constant intravenous (IV) infusion at a rate of 0.4mcg/kg/hour |
|
| Active Comparator: treatment group The treatment group was given dexmedetomidine by constant intravenous (IV) infusion at a rate of 0.4mcg/kg/hour |
Drug: Dexmedetomidine
The treatment group was given dexmedetomidine by constant intravenous (IV) infusion at a rate of 0.4mcg/kg/hour.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- acute kidney injury [7 days]
serum creatinine levels in postoperative 7 days
Secondary Outcome Measures
- early graft dysfunction [7 days]
laboratory data in postoperative 7 days
Eligibility Criteria
Criteria
Inclusion Criteria:
- living liver transplantation recipients
Exclusion Criteria:
-
preoperative renal dysfunction
-
dual living donor liver transplantation
-
severe cerebral artery disease
-
severe cardio-pulmonary disease
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Asan medical center | Seoul | Songpa-gu | Korea, Republic of | 05505 |
Sponsors and Collaborators
- Asan Medical Center
- Kyongbo Pharmaceutical
Investigators
- Principal Investigator: Jun-Gol Song, PhD, Asan Medical Center
Study Documents (Full-Text)
None provided.More Information
Publications
- Cho JS, Shim JK, Soh S, Kim MK, Kwak YL. Perioperative dexmedetomidine reduces the incidence and severity of acute kidney injury following valvular heart surgery. Kidney Int. 2016 Mar;89(3):693-700.
- Liu Y, Sheng B, Wang S, Lu F, Zhen J, Chen W. Dexmedetomidine prevents acute kidney injury after adult cardiac surgery: a meta-analysis of randomized controlled trials. BMC Anesthesiol. 2018 Jan 15;18(1):7. doi: 10.1186/s12871-018-0472-1.
- Rimola A, Gavaler JS, Schade RR, el-Lankany S, Starzl TE, Van Thiel DH. Effects of renal impairment on liver transplantation. Gastroenterology. 1987 Jul;93(1):148-56.
- Wyssusek KH, Keys AL, Yung J, Moloney ET, Sivalingam P, Paul SK. Evaluation of perioperative predictors of acute kidney injury post orthotopic liver transplantation. Anaesth Intensive Care. 2015 Nov;43(6):757-63.
- DEX-LT